Large-scale Registry Study of Patients with Chronic Heart Failure-lessons from the CHART-2 Study

2014 ◽  
Vol 20 (10) ◽  
pp. S141
Author(s):  
Hiroaki Shimokawa
Author(s):  
Natalia S. Meshcherina ◽  
Elena M. Khardikova ◽  
Nina K. Gorshunova ◽  
Natalia V. Abrosimova ◽  
Tatyana S. Leontieva

Despite the development and implementation of clinical guidelines, emergence of modern effective drugs for the treatment of chronic heart failure (CHF), this pathology is characterized by stable progression, directly worsening the quality of life and decreasing the life expectancy. With that, treatment efficacy directly depends on high treatment compliance in patients with CHF both at the treatment start and upon its subsequent correction. One should also not underestimate the value of patient readiness to modify their lifestyle. Besides, the complete physician compliance with clinical guidelines also plays a significant role. The absence of correspondence between principles defined in the guidelines and really administered drugs excludes the possibility of achieving control over CHF symptoms and positive impact on the prognosis. This review is aimed at evaluating treatment compliance among both patients with CHF and their physicians with a focus on Russian studies and good clinical practice (GCP) compared to studies of foreign authors. Unfortunately, the problem of compliance in CHF in the Russian Federation has not been sufficiently analyzed in large-scale studies up to the present time: CHF patient registries mainly allow to detect clinical and epidemiological disease features, while almost not covering compliance issues. It should also be noted that the problem of compliance in both physicians and patients is undoubtedly up-to-date, as it often defines further prognosis in patients with CHF, which explains the scientific practical value of large trials with subsequent thorough analysis and searches regarding increasing its efficiency.


2021 ◽  
Vol 23 (1) ◽  
pp. 84-92
Author(s):  
Anna G. Evdokimova ◽  
◽  
Raisa I. Stryuk ◽  
Vladimir V. Evdokimov ◽  
Anna A. Golikova ◽  
...  

Arterial hypertension is the main risk factor for the development of cardiovascular complications and makes a significant contribution to cardiovascular morbidity, including chronic heart failure, and mortality, amounting to more than 45%. The leading risk factors for the development of cardiovascular diseases also include a violation of lipid and carbohydrate metabolism. Current treatments for cardiovascular disease include the administration of angiotensin II receptor blockers. This article provides an overview of the literature data on the efficacy, safety profile of candesartan, high adherence to this drug in patients with arterial hypertension, chronic heart failure, impaired carbohydrate and lipid metabolism. The advantages of candesartan in comparison with other representatives of this group of drugs in the prevention of chronic heart failure are emphasized according to large-scale international randomized trials. Keywords: arterial hypertension, atherosclerosis, diabetes mellitus, insulin resistance, chronic heart failure, candesartan, Hyposart For citation: Evdokimova AG, Stryuk RI, Evdokimov VV, Golikova AA. Reducing the risk of chronic heart failure development in patients with arterial hypertension from the position of evidence medicine (focus on candesartan). Consilium Medicum. 2021; 23 (1): 84–92. DOI: 10.26442/20751753.2021.1.200730


2020 ◽  
Vol 6 ◽  
Author(s):  
Giuseppe Rosano ◽  
David Quek ◽  
Felipe Martínez

Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to prevent primary and secondary hospitalisation due to heart failure and cardiovascular death in these patients. Data from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) have demonstrated the positive clinical impact of SGLT2 inhibition in patients with heart failure with reduced ejection fraction both with and without T2D. These data have led to the approval of dapagliflozin for the treatment of patients with heart failure with reduced ejection fraction, irrespective of T2D status. This article reviews the latest data reported from the DAPA-HF and EMPEROR-Reduced trials and their clinical implications for the treatment of patients with heart failure.


Author(s):  
O. O. Khaniukov ◽  
L. V. Sapozhnychenko ◽  
M. V. Sаmilyk ◽  
K. D. Perepelytsia

Over the past few years, much attention has been paid to the diagnosis and treatment of myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA). Its prevalence achieves 5 — 15 %, and impact of risk factors of cardiovascular disease development on the MINOCA onset has some specific features. The following criteria are required to diagnose MINOCA: compliance with the MI criteria, absence of obstructive coronary artery disease (≥ 50 %) and exclusion of an alternative diagnosis. Myocardial ischemia is the underlying cause of cardiomyocyte damage during MINOCA. It can be caused by coronary artery thrombosis due to the rupture of atherosclerotic plaque (type 1 MI), spasm or spontaneous coronary artery dissection (type 2 MI). The aim of our study was to analyse risk factors and the incidence of MINOCA in patients with acute myocardial infarction. A retrospective analysis has been performed on 1358 histories of patients with MI who were hospitalized in Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery during the period of 2019 — 2020 years. From them, 60 (4.4 %) patients were selected based on MINOCA diagnostic criteria according to the European Society of Cardiology (2018). The mean age of patients was 58.6 ± 14 years. ST‑segment elevation MI (STEMI) was diagnosed in 87.2 %. Cardiac and non‑cardiac comorbidity has been investigated with the following results: atrial fibrillation (AF) was revealed in 13.3 % of patients, hypertension (AH) — in 85 %, history of coronary heart disease (CHD) — in 31.7 %, recurrent MI — in 11.7 %, chronic heart failure (CHF) — in 75 %, atherosclerosis of peripheral arteries — in 33.3 %, type 2 diabetes mellitus (DM 2) — in 20 %, obesity — in 40.7 %. The proportion of smokers was 43.8 %. According to the results of laboratory studies, dyslipidemia was diagnosed in 44.7 % of patients. According to coronary angiography, 55 % of patients had no coronary artery stenosis, 21.7 % had stenosis of one artery, and stenosis of two or more arteries was defined in 23.3 % of cases. The following distribution by lesions’ types was established: irregularities in the contours of arteries or stenosis up to 30 % in 35 % of cases; stenosis ≥ 30 < 50 % in 18.3 %, and slow evacuation of the contrast agent in 16.7 % of cases. Men prevailed in our research, which is inconsistent with the data of large observational studies, probably due to a small quantity of patients. Hypertension, chronic heart failure, tobacco smoking, obesity and dyslipidemia prevailed among the basic risk factors. Patients with MINOCA require careful evaluation to determine the causative agent and appropriate treatment choices. Conduction of large‑scale studies, in particular, randomized controlled observations, is reasonable and necessary to determine the optimal tactics for management patients with MINOCA.  


Sign in / Sign up

Export Citation Format

Share Document